Asia Pacific Viscosupplementation Market
市场规模（十亿美元）
CAGR :
% 
USD
1.39 Billion
USD
2.89 Billion
2025
2033
 Forecast Period |
2026 –2033 |
 Market Size (Base Year) |
USD 1.39 Billion |
 Market Size (Forecast Year) |
USD 2.89 Billion |
 CAGR |
% |
| Major Markets Players |
|
亚太维斯科补充市场,按来源(动物起源和非动物起源),年龄组(老年和成人),注射(单注射,三注射和五注射),分子重量(中间分子重量,低分子重量和高分子重量),最终用户(医院、矫形诊所、流动护理中心等),分销渠道(直接招标和零售销售)- 2033年工业趋势和预测
亚太维斯科斯补充市场概况
亚太粘合剂市场的价值2025年13.9亿美元预计将达到到2033年达到28.9亿美元,生长在一个2026至2033年CAGR为9.6%市场正在稳步扩大,其驱动力是:骨质炎发病率不断上升,老年病人口不断增加,以及越来越偏好使用侵扰性最小的联合疼痛管理疗法。
老年人膝盖骨炎负担日益加重,加之人们对高血压酸性注射的认识增强,这鼓励医院、矫形诊所和专科护理中心更广泛地采用粘膜补充疗法。 此外,在新兴亚太经济体,注射技术的进步和医疗保健基础设施的扩大进一步支持了市场渗透,因为病人和临床医生越来越多地选择非手术替代品来拖延或避免联合替换程序。
主要市场趋势和见解
- 2025年,中国主导了亚太粘合剂市场,收入份额最大,为35.40%,其支撑力量是骨髓炎负担高,人口老化,矫形护理基础设施不断扩大等。
- 非动物原产地部分在2025年以60.65%的比重带动了市场,其驱动力是临床上对纯度更高和免疫风险较低的生物发酵衍生的hy酸制剂的强烈偏好.
- 印度预计在2026年至2033年CAGR为10.2%,是增长最快的国家市场,这得益于老年病人口的增加、骨质炎发病率的上升、医疗保健的改善以及对非外科联合疼痛治疗的认识的提高。
- 成年人是增长最快的年龄组,预计占CAGR的7.8%,反映出与肥胖、定居生活方式、运动伤害和职业病有关的早期骨质炎病例激增。
- " 三注射 " 部分在2025年占40.50%收入份额的注射类别中占了主导地位,主导这一类别的是整个亚太最广泛采用的膝关节炎管理临床规程。
- 中间分子重量占市场的45.50%,这得益于其粘度、安全和临床疗效的最佳平衡。
- 高分子重量段是增长最快的分子重量类别,CAGR为8.2%,由它的优越长效止痛和降低注射频率要求所驱动.
市场大小和预测
- 全球市场价值(2025年):13.9亿美元
- (2033年):2.89亿美元
- CAGR(2026-2033年):9.6%
- 2025年领先国家:中国
- 最快增长的国家:印度
报告范围和范围亚太维斯科补充市场分割
|
属性 |
亚太维斯科补充键市场透视 |
|
覆盖部分 |
|
|
涵盖国家 |
亚太 中国 * 日本 • 印度 韩国 新加坡 马来西亚 澳大利亚 泰国 印度尼西亚 菲律宾 亚太其他地区 |
|
关键市场玩家 |
• 妇女萨诺菲(法国) • 妇女(原始内容存档于2018-10-12). Fidia Farmaceutici S.p.(意大利) • 妇女艾尼卡治疗公司(美国). • 妇女Seikagaku公司(日本) • 妇女LG Chem有限公司. (韩国) · 山东渤海生物科技有限公司(中国) • Meiji Seika Pharma有限公司(日本) - 三京大一有限公司(日本) · 楚盖制药有限公司(日本) * Kyowa Kirin有限公司(日本) Teva制药工业有限公司(以色列) • Zimmer Biomet(美国) · Johnson & Johnson服务公司(美国) · Bioventus Inc.(美国) • Hyaltech有限公司(英国) Contura International A/S(丹麦) · Smith & Nephew(英国) · Rottapharm Madaus S.p.A.(意大利) · Arthrex公司(美国) Bausch保健(加拿大) |
|
市场机会 |
早期骨质炎患者越来越多地采用激素酸注射法; 扩大私人整形链和专科诊所 · 增加临床上对单注射和高分子重量制剂的偏好 |
|
添加数据信息集的值 |
除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。 |
亚太维斯科补充市场趋势
趋势:向最小侵入性口炎治疗转变
亚太粘合剂市场正在经历一种有力的结构转变,转向最低侵入性治疗方法,特别是心血管酸在动脉内注射,因为病人和临床医生越来越优先考虑膝关节炎的非手术管理。 由于对早期干预的认识不断提高,这一趋势正在得到加强,在早期干预中,推迟或避免完全更换膝盖已成为关键的临床目标。 整形门诊治疗的改善、更快的治疗时间和病人接受重复注射周期的更高程度正在进一步加强收养。 此外,各大医院的最新治疗协议越来越多地建议在外科升级前将粘合剂作为一线或中间疗法。 例如,中国和印度的城市三级医院报告说,随着病人放弃长期康复手术,门诊膝盖注射程序的数量正在增加。
亚太维斯科补充市场动态
主要市场驱动力:脊髓灰质炎和人口老龄化流行率上升
亚太粘合剂市场的主要驱动力是骨质炎发病率迅速上升,这与人口老化、定居生活方式以及中国、日本和印度等主要经济体肥胖率上升密切相关。 随着老年人口的扩大,变性关节障碍的发病率正在加快,形成了对长期疼痛管理疗法的持续需求,保持了关节功能. 由于安全情况更好,而且能够改善多种治疗周期的流动性,因此,Viscosuplement越来越成为皮质类固醇和外科干预的首选替代品。 保健系统也面临减轻外科负担的压力,进一步鼓励早期注射疗法。 例如,日本的矫形科正越来越多地将高血压酸注射纳入老年患者推迟膝盖替换手术的标准化骨髓炎治疗途径。
关键限制/挑战:偿还范围有限和包外费用高
亚太粘合剂行业市场扩张的一大障碍是报销情况不均匀,许多公共保险制度没有完全覆盖动脉内激素酸注入,给患者带来了沉重的财政负担。 这导致负担能力方面的挑战,特别是在中低收入人群中,因为治疗决定对价格高度敏感。 此外,初级保健医生和病人对粘附剂的长期好处认识有限,降低了早期收养率,导致治疗启动延迟或偏好更便宜的止痛药替代品。 整个区域分散的保健筹资结构进一步加剧了城市和农村人口之间的无障碍差距。 例如,在一些东南亚国家,患者往往选择口服止痛药,而不是注射式疗法,因为粘膜补充程序缺乏保险补偿支持。
主要市场机会:扩大新兴经济体的高级矫形护理基础设施
亚太粘合剂市场提供了强劲的增长机会,这是矫形护理基础设施迅速扩大所驱动的,特别是在私人保健投资正在加速的新兴经济体。 越来越多的专科矫形诊所、流动外科中心和医院链的建立,大大改善了病人在大都会地区以外获得联合注射疗法的机会。 这种基础设施的扩大也使得能够采用高保费粘合剂产品,包括单注射和高分子重量配方,这些配方可改善病人的遵守程度和延长耐受期。 此外,越来越多的医疗旅游和私营部门参与正在支持技术转让和更广泛地提供先进的矫形程序。 例如,印度和中国全国二级和三级城市的多专业矫形医院网络的发展,使以前服务不足的病人群体能够更广泛地获得粘膜补充疗法。
亚太维斯科斯补充市场范围
亚太粘合剂市场根据来源、年龄组、注射类型、分子重量、最终用户和分销渠道进行分化。
- 按来源
根据来源,亚太粘合剂市场被分化为动物来源地和非动物来源地. 非动物原生地部分在2025年占据了市场主导地位,其份额估计为60.65%,其驱动力是临床上对纯度较高和免疫风险较低的生物发酵衍生的hy酸制剂的强烈偏好. 由于更严格的监管标准和先进的临床采用做法,日本和韩国等发达的保健系统普遍倾向于这些产品。 医院和矫形专家倾向于非动物原产地配方,因为它们提供一致的分子结构,改进了安全图谱并减少了过敏反应的风险. 跨连通的hy酸技术不断进步,进一步提高了治疗效果和止痛期. 提高医生的认识和以准则驱动的收养也加强了支配地位。 该部分得益于高额医院和专科矫形诊所的大力渗透。
动物起源部分预计将是增长最快的部分,从2026年到2033年的CAGR为8.7%,因为它仍然主要受新兴经济体成本敏感保健系统的驱动。 虽然在某些公共采购方案中仍然广泛使用,但对可变性、净化标准和免疫反应的关切限制了更广泛的采用。 然而,其可负担性确保了农村和半城市保健设施的持续相关性。 随着整个区域安全标准收紧,预计在预测期间将逐步由非动物制剂取而代之。
- 按年龄组
根据年龄组,市场分为老年和成人两个部分。 2025年,由于中国、日本和印度等国家老年人口中骨质炎发病率高,老年部分在市场上占据了主导地位,估计占70.75%。 与年龄有关的软骨分解,关节润滑减少,流动性受限,大大增加了这些人群对粘膜补充疗法的需求. 医院普遍倾向于为老年患者注射可激素酸治疗,作为总膝盖置换等外科手术干预的更安全的替代品. 预期寿命的提高和接受矫形护理的机会的改善正在进一步加强市场支配地位。 在某些国家,政府领导的老年人保健方案和保险支助也有助于提高收养率。 这一部分仍然是整个亚太的核心收入贡献。
成人部分预计将是增长最快的部分,在2026年至2033年期间登记了7.8%的CAGR,其驱动力是与肥胖、定居生活方式、运动伤害和职业紧张有关的早期骨质炎病例增加。 年轻病人越来越多地选择预防性联合护理,以推迟疾病发展,避免晚年的外科手术。 人们对非手术治疗方案的认识日益提高,诊断率得到提高,这正在鼓励早期的干预。 扩大的矫形诊所网络和门诊护理设施正在改善工作年龄人口的就诊机会。 越来越多的体育参与和与伤害有关的关节疾病进一步加速了这一环节对粘膜补充疗法的需求。
- 按注射类型
根据注射类型,市场分为单次注射,三次注射,五次注射. 2025年, " 三注射 " 部分在市场上占据了大约40.45%的份额,因为它仍然是整个亚太最广泛采用的膝关节炎管理临床规程。 它倾向于在费用、临床效果和医生的熟悉程度之间采取平衡的办法。 由于长期临床验证和可预测的治疗结果,许多治疗准则仍然建议采用多剂量治疗方法。 医院和矫形诊所继续依靠这一程序治疗中性骨炎病例。 若干国家的偿还结构也倾向于多注射方法,而不是高价的单剂量替代品。 强有力的医生信任和历史使用模式继续强化支配地位。
单一注射部分预计将是增长最快的部分,2026年至2033年登记了8.5%的CAGR,其驱动力是病人对方便的偏好增加,就诊次数减少,遵守规定的情况改善. 高分子重量和相通配方的进步使疗效得到显著提高,使单剂量疗法成为多注射药剂的有力替代品. 门诊护理的扩大和时间效率高的治疗模式正在进一步支持收养。 由于程序负担减轻,医生越来越多地建议对轻度至中度骨炎病例采用单注射疗法。 快速、有效和最小程度破坏性治疗方案的需求日益增加,正在加速这一部门的增长。
- 由分子重量
根据分子重量,市场被分割成低分子重量,中分子重量,高分子重量. 中间分子重量部分由于在粘度、安全性和临床疗效方面保持了最佳平衡,在2025年市场占有约45.50%的份额。 它被广泛用作整个亚太的医院和矫形诊所的标准治疗方案。 医生更喜欢这一类,因为它提供持续的疼痛缓解,持续时间适中,安全情况良好。 它还为成本和治疗结果提供了有利的平衡,使之适合大量病人。 公共和私人保健系统的强劲供应进一步支持了支配地位。 该分会仍然是常规骨炎治疗中最常用的处方型.
高分子重量段预计将是增长最快的部分,在2026年至2033年注册的CAGR为8.2%,由它的优越的长效止痛和降低注射频率要求所驱动. 在需要延长症状控制的中度至重度骨质炎病例中,这种治疗越来越可取。 互联互通技术的进步,改善了稳定性,居住时间,临床表现. 医院越来越多地转向保费配方,以提高病人的满意度和治疗结果。 本区域对单注射、长期疗法的需求正在进一步加快。
- 按终端用户
在最终用户的基础上,市场分为医院、矫形诊所、流动护理中心等。 2025年,在患者大量流入、诊断能力先进以及有熟练的矫形专家的推动下,医院部分在市场中占了大约55.60%的份额。 医院仍然是需要结构性注射治疗和后续护理的中度至重度骨质炎病例的主要治疗中心。 强有力的机构采购制度和偿还支助进一步加强了支配地位。 他们还充当复杂的关节疾病和高级治疗规划的转诊中心。 整个三级保健医院的程序量很高,继续保持领导地位。 这部分人受益于完善的基础设施和多学科护理小组。
由于对门诊治疗模式和成本效益高的保健服务的需求不断上升,预计门诊护理中心部分在2026年至2033年期间的CAGR为9.1%,增长最快。 由于等候时间更短、程序更快以及总体治疗费用更低,病人越来越喜欢这些中心。 新兴亚太经济体私人保健基础设施的扩大正在大大改善获得保健服务的机会。 医生将常规粘膜补充程序转移到门诊场所,以提高效率。 整形护理的权力下放日益扩大,日托程序日益受到重视,这进一步加快了增长。
- 按发行频道
以发售渠道为基础,将市场分入直接招标和零售. 2025年,直接招标部分在政府医院、公共保健系统和机构购买者大宗采购的驱动下,在市场中占了大约65.70%的份额。 这一渠道能够实现成本效益高的购买、长期供应稳定以及大型医院网络的标准化采购。 在中国和印度等公共保健系统较强的国家,这种疾病尤为严重。 医院更倾向于这一渠道,因为价格可以预测,采购过程可以简化。 政府主导的保健方案和集中采购机制继续强化支配地位。 该部分仍然是整个亚太大规模市场分布的支柱。
零售销售部门预计将是增长最快的部门,在2026至2033年注册的CAGR为8.6%,其驱动力是扩大私人整形诊所、专科中心和分散的医疗保健提供模式。 增加病人获得门诊治疗的机会正在加强直通诊所的产品流动。 改进的药品分销网络正在加强城市和半城市地区的产品供应。 私人保健支出和医疗旅游不断增加,进一步推动了增长。 转向以病人为中心、以方便为驱动的治疗途径正在加速整个区域的零售渠道扩张。
亚太维斯科补充市场区域分析
2025年,中国主导了亚太粘合剂市场,收入份额最大,为35.40%,其支撑力量是骨髓炎负担高,人口老化,矫形护理基础设施不断扩大等。 该国还受益于越来越多地采用以羟氨酸为基础的注射作为膝关节炎的首选非手术治疗方案,特别是在门诊医院。 不断增加的保健支出、改善获得高级矫形疗法的机会以及对联合保存治疗的认识的提高,都进一步加强了市场渗透。 扩大大型医院网络,增加一级和二级城市的程序量,继续支持中国在亚太粘贴市场的领导地位。
中国维斯科补充市场透视
由于骨质炎负担过重,人口老化,整形护理基础设施在城市和二级城市的强劲扩展,中国粘合剂市场正在快速增长。 越来越多地采用羟氨酸注射作为首选的非外科治疗方法,大大支持了医院和专科矫形诊所的市场需求。 该国还受益于不断增加的保健投资、改善获得高级联合护理疗法的机会以及对早期骨髓炎管理的认识。 扩大大型医院网络和增加门诊程序,进一步加强了中国在亚太粘合剂市场的主导地位.
日本维斯科补充市场透视
日本粘合剂市场稳步增长,原因是全球老龄化人口最多,老年病人中膝关节炎发病率高。 国家已普遍接受以羟氨酸为基基的注射,作为关节疼痛管理的标准非外科治疗. 包括高分子重量粘滞剂在内的先进制剂日益融合,进一步支撑了临床采纳. 强有力的保健基础设施、对病人的高度认识以及注重保持老龄人口的流动继续推动市场增长。 此外,日本强调预防保健和减少外科依赖性,这进一步加强了粘附补充需求。
印度维斯科斯补充市场透视
印度粘合剂市场由于骨质炎病例增加、老年人口增加以及城市和半城市地区获得整形护理的机会增加而迅速增长。 人们对非外科治疗选择的认识日益提高,对hy酸注射的可负担性也日益提高,这正在推动私立医院和专科诊所的收养。 整形链和流动护理中心的扩大正在进一步改善治疗的可获性。 与生活方式有关的连带障碍增加和运动伤害增加,也是导致需求增加的原因之一。 加强保健基础设施和病人越来越喜欢成本效益高的疼痛管理疗法,使印度成为该区域增长最快的市场之一。
韩国维斯科斯补充市场透视
韩国粘合剂市场稳步增长,原因是骨质炎发病率上升,人口老化,医院和专科诊所大力采用先进的矫形治疗技术。 该国得益于高度发达的保健系统、对病人的高度认识以及早期采用最低侵入性程序,如为膝关节炎注射高血压酸。 越来越倾向于非外科疼痛管理解决方案,越来越注重保持老年人口流动,进一步支持了市场扩张. 此外,配方技术的持续进步和私人保健提供者的大力渗透正在提高治疗的可获性和临床的采用。 韩国日益重视门诊矫形护理和预防联合健康管理,这继续加强了韩国在亚太粘合剂市场的地位。
亚太维斯科补充市场份额
亚太粘合剂工业主要由历史悠久的公司领导,包括:
- 萨诺菲(法国)
- Fidia Farmaceutici S.p.A.(意大利)
- Anika治疗有限公司(美国)
- Seikagaku公司(日本)
- LG Chem有限公司(韩国)
- 山东渤海生物科技有限公司(中国).
- Meiji Seika Pharma有限公司(日本)
- 大一三京有限公司(日本)
- 楚盖制药有限公司(日本)
- Kyowa Kirin有限公司(日本)
- Teva制药工业有限公司(以色列)
- Zimmer Biomet (美国).
- Johnson & Johnson服务公司(美国)
- Bioventus Inc. (美国).
- Hyaltech有限公司 (英国).
- 康图拉国际协会(丹麦)
- 史密斯与侄子 (英国).
- 罗塔法尔·马道斯·斯皮克(意大利)
- Arthrex公司(美国)
- Bausch保健公司(加拿大)
亚太维斯科补充市场的最新动态
- 2024年3月,以克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏克氏 该公司强调,由于其长期的临床疗效和安全情况,它越来越多地在整形诊所使用膝盖骨节炎治疗。 这一发展反映出亚太区域老龄化人口对基于医管局的粘合剂的需求增加。
- 2023年6月,大型生命科学公司"LG Chem"(韩国)推进了包括"Hyruan One"在内的"羟氨酸联合注射组合"的商业化和扩展,针对的是亚洲市场日益增长的对骨髓炎治疗的需求. 该公司强调在国内和区域保健系统中进行更广泛的分配,以解决日益增多的联发性失调病例。 这反映了韩国在先进的粘接制造和收养方面日益起的作用。
- 2022年9月,"渤海生物科技"(中国)作为眼科和矫形生物材料的关键角色,宣布其hy酸注射产品在国内矫形治疗市场被扩大应用. 该公司基于HA的可注射产品在中国各医院的膝关节炎管理中继续获得牵引力,原因是对最低侵入性疗法的需求不断增加。 这凸显出中国加强粘合剂产品国内供应链
- 2022年5月,以羟氨酸为基础的疗法全球领先者Fidia Farmaceutici(意大利)扩大了其在亚太市场的分销伙伴关系,以加强对Hyalgan粘合剂产品的获取。 该公司的重点是增加亚洲新兴经济体骨髓灰质炎发病率正在上升的矫形诊所的供应。 这一扩展反映了区域对已建立的HA注射疗法的需求日益增加。
- 2021年7月,萨诺菲(法国)通过其Genzyme分会,继续通过区域保健分配渠道,加强全亚太市场的Synvisc(hylan G-F 20)的提供和临床使用,特别是在印度和东南亚. 在寻求非外科疼痛缓解方案的患者中,该疗法仍然被广泛用于膝盖骨炎管理. 这突出表明,在发展APAC卫生保健系统时,继续依赖既有的粘合剂品牌。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC VISCOSUPPLEMENTATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
7 PIPELINE ANALYSIS FOR ASIA PACIFIC VISCOSUPPLEMENTATION MARKET
8 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: REGULATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING GERIATRIC POPULATION
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS
9.2 RESTRAINTS
9.2.1 LACK OF TECHNICAL EXPERTISE
9.2.2 PRODUCT RECALL PROCEDURES
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION
9.3 OPPORTUNITIES
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA)
9.3.2 RISING HEALTHCARE INFRASTRUCTURE
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT
9.4 CHALLENGES
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION
10 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NON-ANIMAL ORIGIN
10.2.1 ORTHOVISC
10.2.2 EUFLEXXA
10.2.3 MONOVISC
10.2.4 DUROLANE
10.2.5 GEL-ONE
10.2.6 SUPARTZ
10.2.7 GELSYN-3
10.2.8 CINGAL
10.2.9 SULPLASYN
10.2.10 VISCOSEAL
10.2.11 OSTEONIL
10.2.12 OTHERS
10.3 ANIMAL ORIGIN
10.3.1 HYLAN G-F 20
10.3.2 SYNVIC ONE
10.3.3 SYNVIC
10.3.4 OTHERS
10.3.5 HYALURONANS
10.3.6 HYALGAN
10.3.7 OTHERS
11 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT
11.1 OVERVIEW
11.2 INTERMEDIATE MOLECULAR WEIGHT
11.2.1 ORTHOVISC
11.2.2 EUFLEXXA
11.2.3 MONOVISC
11.2.4 DUROLANE
11.2.5 VISCOSEAL
11.2.6 OSTEONIL
11.2.7 OTHERS
11.3 LOW MOLECULAR WEIGHT
11.3.1 HYLAGAN
11.3.2 SUPARTZ
11.3.3 GELSYN-3
11.3.4 CINGAL
11.3.5 SULPLASYN
11.3.6 OTHERS
11.4 HIGH MOLECULAR WEIGHT
11.4.1 SYNVIC ONE
11.4.2 SYNVIC
11.4.3 OTHERS
12 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY INJECTION
12.1 OVERVIEW
12.2 SINGLE INJECTION
12.3 THREE INJECTION
12.4 FIVE INJECTION
13 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
14 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 ORTHOPEDIC CLINICS
14.4 AMBULATORY CARE CENTERS
14.5 OTHERS
15 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.3 DIRECT TENDER
16 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 INDIA
16.1.3 JAPAN
16.1.4 AUSTRALIA
16.1.5 MALAYSIA
16.1.6 THAILAND
16.1.7 SINGAPORE
16.1.8 SOUTH KOREA
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 TAIWAN
16.1.12 VIETNAM
16.1.13 REST OF ASIA-PACIFIC
17 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JOHNSON & JOHNSON SERVICES, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 BIOVENTUS
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 FERRING B.V.
19.3.1 COMPANY SNAPSHOT
19.3.2 COMPANY SHARE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 SANOFI-AVENTIS U.S. LLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 ZIMMER BIOMET
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 SEIKAGAKU CORPORATION
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ANIKA THERAPEUTICS, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 FIDIA FARMACEUTICI S.P.A
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 APTISSEN
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 IBSA INSTITUT BIOCHIMIQUE SA
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 LG CHEM.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS)
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 ORTOBRAND INTERNATIONAL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 TRB CHEMEDICA SA
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENTS
19.17 VIATRIS INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 VIRCHOW BIOTECH
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC NON-ANIMAL IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 5 ASIA PACIFIC ANIMAL IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 9 ASIA PACIFIC HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 11 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC SINGLE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC THREE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC FIVE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC ADULT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC GERIATRIC IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC HOSPITALS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC ORTHOPEADIC CLINICS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC AMBULATORY CARE CENTERS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC OTHERS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC RETAIL SALES IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC DIRECT TENDER IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 37 ASIA-PACIFIC ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 40 ASIA-PACIFIC HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 42 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 CHINA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 51 CHINA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 52 CHINA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 53 CHINA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 54 CHINA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 CHINA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 56 CHINA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 57 CHINA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 58 CHINA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 59 CHINA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 60 CHINA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 61 CHINA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 62 CHINA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 63 CHINA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 64 CHINA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 CHINA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 INDIA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 67 INDIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 68 INDIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 69 INDIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 70 INDIA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 INDIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 72 INDIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 73 INDIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 74 INDIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 75 INDIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 76 INDIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 77 INDIA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 78 INDIA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 79 INDIA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 80 INDIA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 81 INDIA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 82 INDIA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 83 INDIA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 INDIA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 JAPAN VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 86 JAPAN NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 87 JAPAN NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 88 JAPAN NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 89 JAPAN ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 JAPAN HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 91 JAPAN HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 92 JAPAN HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 93 JAPAN VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 94 JAPAN INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 95 JAPAN HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 96 JAPAN VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 97 JAPAN VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 98 JAPAN VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 99 JAPAN VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 100 AUSTRALIA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 101 AUSTRALIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 102 AUSTRALIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 103 AUSTRALIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 104 AUSTRALIA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 AUSTRALIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 106 AUSTRALIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 107 AUSTRALIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 108 AUSTRALIA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 109 AUSTRALIA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 112 AUSTRALIA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 113 AUSTRALIA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 114 AUSTRALIA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 115 AUSTRALIA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 116 MALAYSIA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 117 MALAYSIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 118 MALAYSIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 119 MALAYSIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 120 MALAYSIA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 MALAYSIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 122 MALAYSIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 123 MALAYSIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 124 MALAYSIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 125 MALAYSIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 126 MALAYSIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 127 MALAYSIA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 128 MALAYSIA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 129 MALAYSIA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 130 MALAYSIA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 131 MALAYSIA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 132 MALAYSIA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 133 MALAYSIA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 MALAYSIA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 THAILAND VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 136 THAILAND NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 137 THAILAND NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 138 THAILAND NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 139 THAILAND ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 THAILAND HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 141 THAILAND HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 142 THAILAND HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 143 THAILAND HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 144 THAILAND HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 145 THAILAND HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 146 THAILAND VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 147 THAILAND INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 148 THAILAND LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 149 THAILAND HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 150 THAILAND VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 151 THAILAND VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 152 THAILAND VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 153 THAILAND VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 154 SINGAPORE VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 155 SINGAPORE NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 156 SINGAPORE NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 157 SINGAPORE NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 158 SINGAPORE ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 SINGAPORE HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 160 SINGAPORE HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 161 SINGAPORE HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 162 SINGAPORE HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 163 SINGAPORE HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 164 SINGAPORE HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 165 SINGAPORE VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 166 SINGAPORE INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 167 SINGAPORE LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 168 SINGAPORE HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 169 SINGAPORE VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 170 SINGAPORE VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 171 SINGAPORE VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 172 SINGAPORE VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 173 SOUTH KOREA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 174 SOUTH KOREA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 175 SOUTH KOREA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 176 SOUTH KOREA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 177 SOUTH KOREA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SOUTH KOREA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 179 SOUTH KOREA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 180 SOUTH KOREA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 181 SOUTH KOREA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 182 SOUTH KOREA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 183 SOUTH KOREA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 184 SOUTH KOREA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 185 SOUTH KOREA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 186 SOUTH KOREA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 187 SOUTH KOREA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 188 INDONESIA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 189 INDONESIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 190 INDONESIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 191 INDONESIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 192 INDONESIA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 INDONESIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 194 INDONESIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 195 INDONESIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 196 INDONESIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 197 INDONESIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 198 INDONESIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 199 INDONESIA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 200 INDONESIA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 201 INDONESIA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 202 INDONESIA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 203 INDONESIA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 204 INDONESIA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 205 INDONESIA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 206 INDONESIA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 207 PHILIPPINES VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 208 PHILIPPINES NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 209 PHILIPPINES NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 210 PHILIPPINES NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 211 PHILIPPINES ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 PHILIPPINES HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 213 PHILIPPINES HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 214 PHILIPPINES HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 215 PHILIPPINES HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 216 PHILIPPINES HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 217 PHILIPPINES HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 218 PHILIPPINES VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 219 PHILIPPINES INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 220 PHILIPPINES LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 221 PHILIPPINES HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 222 PHILIPPINES VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 223 PHILIPPINES VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 224 PHILIPPINES VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 225 PHILIPPINES VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 226 TAIWAN VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 227 TAIWAN NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 228 TAIWAN NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 229 TAIWAN NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 230 TAIWAN ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 231 TAIWAN HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 232 TAIWAN HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 233 TAIWAN HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 234 TAIWAN HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 235 TAIWAN HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 236 TAIWAN HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 237 TAIWAN VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 238 TAIWAN INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 239 TAIWAN LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 240 TAIWAN HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 241 TAIWAN VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 242 TAIWAN VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 243 TAIWAN VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 244 TAIWAN VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 245 VIETNAM VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 246 VIETNAM NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 247 VIETNAM NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 248 VIETNAM NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 249 VIETNAM ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 VIETNAM HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 251 VIETNAM HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 252 VIETNAM HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, VOLUME, 2020-2029 (ASP, USD)
TABLE 253 VIETNAM HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 254 VIETNAM HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 255 VIETNAM HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 256 VIETNAM VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 257 VIETNAM INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 258 VIETNAM LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 259 VIETNAM HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 260 VIETNAM VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 261 VIETNAM VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 262 VIETNAM VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 263 VIETNAM VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 264 REST OF ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 THE INCREASING DEMAND FOR NON-SURGICAL TREATMENTS FOR OSTEOARTHRITIS AND ADVANCEMENTS IN THE DEVELOPMENT OF HYALURONIC ACID-BASED THERAPIES IS EXPECTED TO DRIVE THE ASIA PACIFIC VISCOSUPPLEMENTATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 NON-ANIMAL ORIGIN IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC VISCOSUPPLEMENTATION MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC VISCOSUPPLEMENTATION MARKET
FIGURE 15 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY SOURCE, 2021
FIGURE 16 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY SOURCE, 2022-2029 (USD MILLION)
FIGURE 17 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY SOURCE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, 2021
FIGURE 20 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY INJECTION, 2021
FIGURE 24 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY INJECTION, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY INJECTION, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY INJECTION, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, 2021
FIGURE 28 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY END USER, 2021
FIGURE 32 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 36 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET: SNAPSHOT (2021)
FIGURE 40 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2021)
FIGURE 41 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 ASIA-PACIFIC VISCOSUPPLEMENTATION MARKET: BY SOURCE (2022-2029)
FIGURE 44 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
